Pancreatic Cancer Research

ResearcherConsejo Superior de Investigaciones CientíficasActive in the last 2 years

Bruno Sáinz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4829-7651; OpenAlex author ID A5031406092, A5141180920. Sources: OpenAlex.

Their work

Papers
54 (first author 1, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
153
Papers, trials and grants by year

2013: 1 paper · 2014: 3 papers · 2015: 4 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 4 papers · 2020: 8 papers · 2021: 9 papers · 2022: 3 papers · 2023: 5 papers · 2024: 3 papers · 2025: 4 papers · 2026: 5 papers

Papers 50 of 54

  1. A CXCR4 targeting peptide delivered by silica nanoparticles eliminates migrating cancer stem cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-026-48584-2↗
  2. Aptamer-based inhibition of MNK1 reduces pancreatic ductal adenocarcinoma growth by targeting cancer stem cells. Last author DOI 10.1186/s12929-026-01275-6↗
  3. Evaluation of Self-Illuminating Nanoconjugates Against Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2147/ijn.s545161↗
  4. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  5. Mechanobiology-guided drug repurposing identifies budesonide as an inhibitor of stiffness-induced PDAC aggressiveness Co-author DOI 10.64898/2026.07.17.739125↗
  6. TGF-β1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and … Co-author DOI 10.1038/s41419-025-07859-8↗
  7. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Co-author DOI 10.1073/pnas.2523039122↗
  8. PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3475↗
  9. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Co-author DOI 10.1186/s12943-025-02486-5↗
  10. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Last author DOI 10.1136/gutjnl-2023-330995↗
  11. Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis. Last author DOI 10.1186/s12951-024-03010-5↗
  12. Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism. Co-author DOI 10.1186/s13046-024-03072-1↗
  13. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival. Co-author DOI 10.1016/j.biopha.2023.115179↗
  14. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Last author DOI 10.1136/gutjnl-2021-325564↗
  15. Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential. Co-author DOI 10.1186/s13046-023-02858-z↗
  16. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. Co-author DOI 10.1186/s13046-023-02883-y↗
  17. Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue. Co-author DOI 10.3791/65229↗
  18. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2022.100815↗
  19. LAMC2 marks a tumor-initiating cell population with an aggressive signature in pancreatic cancer. Co-author DOI 10.1186/s13046-022-02516-w↗
  20. Targeting BPTF Sensitizes Pancreatic Ductal Adenocarcinoma to Chemotherapy by Repressing ABC-Transporters and Impairing Multidrug Resistance (MDR). Co-author DOI 10.3390/cancers14061518↗
  21. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  22. PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer Co-author DOI 10.1101/2021.11.15.468579↗
  23. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-319970↗
  24. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug. Co-author DOI 10.1186/s13046-021-02153-9↗
  25. Inhibition of Mitochondrial Dynamics Preferentially Targets Pancreatic Cancer Cells with Enhanced Tumorigenic and Invasive Potential. Co-author DOI 10.3390/cancers13040698↗
  26. The Revolutionary Roads to Study Cell-Cell Interactions in 3D In Vitro Pancreatic Cancer Models. Co-author DOI 10.3390/cancers13040930↗
  27. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer O… Co-author DOI 10.3390/cancers13071612↗
  28. Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. Co-author DOI 10.3390/cancers13133145↗
  29. Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS N… Co-author DOI 10.3390/cancers13153687↗
  30. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Last author DOI 10.1038/s41467-020-16395-2↗
  31. Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells. Last author DOI 10.1038/s41467-020-18954-z↗
  32. A feedback-loop between telomerase activity and stemness factors regulates PDAC stem cells Co-author DOI 10.1101/2020.11.02.361931↗
  33. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response. Co-author DOI 10.1177/2050640620905183↗
  34. Induction of Lysosome Membrane Permeabilization as a Therapeutic Strategy to Target Pancreatic Cancer Stem Cells. Last author DOI 10.3390/cancers12071790↗
  35. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Last author DOI 10.3390/ijms21207437↗
  36. Correction: Alcalá, S., et al. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Int. J. Mol. Sci. 2020, 21, 7437. Last author DOI 10.3390/ijms21239215↗
  37. Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells. Co-author DOI 10.4252/wjsc.v12.i11.1410↗
  38. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Last author DOI 10.1038/s41388-019-0803-9↗
  39. The Anthrax Toxin Receptor 1 (ANTXR1) Is Enriched in Pancreatic Cancer Stem Cells Derived from Primary Tumor Cultures. Last author DOI 10.1155/2019/1378639↗
  40. MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo. Co-author DOI 10.1155/2019/8475389↗
  41. EMT and Stemness-Key Players in Pancreatic Cancer Stem Cells. Co-author DOI 10.3390/cancers11081136↗
  42. Pancreatic cancer stem cells: A state or an entity? First author DOI 10.1016/j.semcancer.2018.08.007↗
  43. The Ever-Evolving Concept of the Cancer Stem Cell in Pancreatic Cancer. Last author DOI 10.3390/cancers10020033↗
  44. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311256↗
  45. The ever-changing landscape of pancreatic cancer stem cells. Last author DOI 10.1016/j.pan.2016.04.004↗
  46. DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster. Last author DOI 10.1158/0008-5472.can-15-3268↗
  47. MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Co-author DOI 10.1016/j.cmet.2015.08.015↗
  48. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2014-308470↗
  49. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Co-author DOI 10.1136/gutjnl-2014-308935↗
  50. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Co-author DOI 10.1158/1078-0432.ccr-14-1399↗

Closest collaborators

The 25 strongest of 153 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sonia Alcalá · 23 shared papers, 2015–2026 · strength 2.89
  2. Christopher Heeschen · 21 shared papers, 2013–2025 · strength 1.92
  3. Patrick Christian Hermann · 18 shared papers, 2013–2026 · strength 1.83
  4. Patricia Sancho · 13 shared papers, 2014–2026 · strength 1.39
  5. Juan Carlos López-Gil · 8 shared papers, 2020–2026 · strength 1.25
  6. Julie Earl · 9 shared papers, 2019–2026 · strength 1.15
  7. Enza Lonardo · 6 shared papers, 2015–2026 · strength 0.95
  8. Alfredo Carrato · 7 shared papers, 2019–2024 · strength 0.79
  9. Karolin Walter · 7 shared papers, 2019–2026 · strength 0.74
  10. Thomas Theodor Werner Seufferlein · 7 shared papers, 2019–2026 · strength 0.73
  11. Carmen E. Guerra · 5 shared papers, 2014–2026 · strength 0.70
  12. Donatella Delle Cave · 4 shared papers, 2021–2025 · strength 0.65
  13. Gabriella Minchiotti · 3 shared papers, 2024–2026 · strength 0.62
  14. Beatriz Parejo-Alonso · 4 shared papers, 2021–2026 · strength 0.60
  15. Petra Jagušt · 5 shared papers, 2015–2025 · strength 0.58
  16. Frank Arnold · 5 shared papers, 2020–2026 · strength 0.58
  17. Alexander Kleger · 5 shared papers, 2020–2026 · strength 0.58
  18. Sandra Valle · 6 shared papers, 2018–2023 · strength 0.58
  19. Kanishka Tiwary · 5 shared papers, 2019–2026 · strength 0.57
  20. Sara Maria David Trabulo · 7 shared papers, 2013–2025 · strength 0.56
  21. Paola Martinelli · 6 shared papers, 2014–2023 · strength 0.50
  22. Kıvanç Görgülü · 4 shared papers, 2021–2025 · strength 0.49
  23. Hana Algül · 4 shared papers, 2021–2025 · strength 0.49
  24. Eva Rodríguez-Aznar · 5 shared papers, 2019–2021 · strength 0.48
  25. Marcelina Abal-Sanisidro · 2 shared papers, 2024–2026 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.